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OUTCOME OF CHINESE CHILDREN WITH UNRELATED DONOR HEMATO-
POIETIC STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERI-
ENCE
Chen, J., Luo, C., Jiang, H., Luo, C., Tang, J., Gu, L. Shanghai Jiao
Tong University School of Medicine, Shanghai Children’s Medical Center,
Shanghai, China
Background: To evaluate the outcome and prognostic factors in
Chinese children undergoing matched unrelated donor hematopoi-
etic stem cell transplantation (UDT).
Methods: Retrospective analysis of clinical data of 53 consecutive
children received URT between November 2002 to December
2007 in our center was performed. Conditioning regimen for Acute
lymphoblastic leukemia (ALL) was total body irradiation based,
aplastic anemia (AA) was fludarabine based. The other patients re-
ceived busulphan based myeloablative regimen.
Results:Themedian age was 8.4 years (range, 1.521) with the me-
dian follow up 36 months (range, 1880). The probability of 3-year
overall survival (OS) was 71.5%.Treatment relatedmortality (TRM)
was 19.0%. 9.4% died after post-transplant leukemia relapse. Inci-
dence of Grade I-II and III-IV acute and chronic GVHD was
63%, 29% and 46%. There was significant difference of OS for pa-
tients older or younger than 10 years(50.0% vs 84.8%, p5 0.003)and
patients with different underlying diseases (ALL, AML, CML and
non-malignant disease: 36.4%, 80.0%, 61.5% and 100%,
p5 0.001). There was also significant difference of OS for patients
with low-risk, high-risk leukemia (83.3% vs 42.9%, p5 0.013) and
patient received HLA 0-1 locus 2-3 loci high resolution mismatched
transplant (83.3% vs 53.3%, p5 0.034). But there was no significant
difference of OS among the patient received peripheral stem cell,
bone marrow or cord blood transplant (70.3%,87.5%,62.5%,
p5 0.542) and patients with 0-II and III-IV acute GVHD (77.8%
vs 60.0%, p5 0.140).
Conclusions: The important prognostic factors for OS after UDT
were the degree of HLAmatch, the age of patient and the type of un-
derlying disease. Patients less than 10 year with non-malignant dis-
ease receiving 0-1 locus high resolution mismatched UDT had the
best outcome. Myeloid, low-risk leukemia was superior to other leu-
kemia.373
IV BUSULFAN-BASED REDUCED INTENSITY REGIMEN (RIC) BEFORE AL-
LOGENEIC STEM CELL TRANSPLANTATION IS WELL TOLERATE AND EF-
FECTIVE IN PATIENTS WITH HEMATOLOGICAL DISEASES
Castagna, L.1, Fu¨rst, S.1, El-Cheikh, J.1, Faucher, C.1, Vey, N.1,
Bouabdallah, R.1, Stoppa, A.-M.1, Mohty, M.2, Chabannon, C.1,
Esterni, B.3, Blaise, D.1 1 Institut Paoli Calmettes, Marseille, France;
2 CHU Hotel Dieu, Nantes, France; 3 Institut Paoli Calmettes, Marseille,
France
Background: Busulfan-based RIC has been widely used in Alloge-
neic setting, showing good safety profile and efficacy. The intrave-
nous formulation, Busilvex, is considered a step forward as
compared to oral form because of reproducible biodisponibility
and pharmacokinetic. In this study, we evaluated the toxic profile
and clinical efficacy of a busilvex-based RIC.
Patients and methods: Since 2005, 78 patients received a uniform
RIC consisting of busilvex 3.2 mg/kg/day for 2 days, Fludarabine
40 mg/m2/days for 5 days, and thymoglobulin 2.5 mg/kg/day for 2
days. Cyclosporine was used as post-graft immunesuppression.
The median age was 58 years (24-70), and 41% of patients suffered
from acute myeloid leukemia. 81% were in complete or partial re-
mission before RIC. Donor was a HLA identical sibling for 64%
of patients. 43% of patients received previous high dose chemother-
apy.
Results: The median follow-up was 16 (2-51). No patients devel-
oped venocclusive disease (VOD). The cumulative incidence (CI)
for grade II-IV acute graft versus host disease (GVHD) was
31%, and for extensive chronic GVHD was 25%. Overall 9 pts
died from TRM for a 2 year CI of 16% (8-28). In addition, 18
pts relapsed or progressed for a 2 year CI of relapse progression
of 30% (17-48). Overall the 2-y overall survival (OS) and diseasefree survival (DFS) probabilities were respectively 71% (56-82)
and 58% (42-72).
Conclusions: This retrospective study shows that busilvex-based
RIC is well tolerate with low TRM incidence in a high-risk cohort
of patients. Particularly, the extensive chronic GVHD incidence
was low probably due to thymoglobulin use for HLA identical do-
nors. VOD was absent even if reversible hepatic toxicity was fre-
quently observed. These promising safety results invited us to
assess the impact of higher dose of IV Busulfan in an ongoing trial
in order to improve disease control.374
OUTCOMES AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANS-
PLANTATION FOR PATIENTS WITH ADVANCED CHRONIC LYMPHOCYTIC
LEUKEMIA
Rashed, A., Corringham, S., Castro, J.E., Kipps, T.J., Ball, E.D. Univer-
sity of California, San Diego, La Jolla, CA
Allogeneic hematopoietic stem cell transplantation (HSCT) is
a treatment increasingly used for patients with chronic lympho-
cytic leukemia (CLL). There is no curative treatment for patients
with advanced CLL. However, prolonged disease-free survival
has been shown in patients after allogeneic HSCT. The aim of
the study was to analyze the outcome of patients with CLL
treated at our institution with either non-myeloablative (n5 12)
or myeloablative (n5 1) conditioned allogeneic HSCT. Thirteen
patients (5 males [5 Caucasian], 8 females [7 Caucasian, 1 His-
panic]) diagnosed with CLL who underwent allogeneic HSCT
from related (n5 7) and unrelated (n5 6) donors between No-
vember 1998 and July 2009 were included in this analysis. The
median age was 55 (age range 47-75), median interval between
diagnosis and HSCT was 1,556 days, and the median number
of regimens prior to transplant was 5 (range 2-7). Of the 13 pa-
tients, 5 were fludarabine-refractory and 1 was not evaluable
(NE). 12 patients received a fludarabine-based non-myeloablative
conditioning regimen, while 1 patient received an ablative cyclo-
phosphamide/total body irradiation regimen. Prior to transplant,
4 patients had progressive disease (PD), 6 patients were in partial
remission (PR), and 3 patients were in complete remission (CR).
Disease status was re-assessed 30 days post allogeneic HSCT. At
this time post-transplant, 6 patients were in CR, 4 were in PR, 1
was in stable disease (SD), 1 had PD, and 1 was NE. Thus, at
day 30, 11 of the 13 patients improved or were stable. Of the
remaining 2 patients, 1 continued to progress and 1 died of
multi-organ failure 16 days post transplant. At the time of this
report, median times to progression and overall survival were
467 and 1,843 days respectively. The Kaplan-Meier probabilities
of progression-free survival (PFS) and overall survival (OS) at
three-years were 43% and 84%, and the five-year PFS and OS
were 43% and 43%, respectively. Differences in the outcomes
were not apparent between matched related and unrelated do-
nors. Our results indicate that long-term survival after allogeneic
HSCT can be achieved in heavily pre-treated high-risk CLL pa-
tients. This treatment should be offered to patients with matched
donors and good performance status that have demonstrated
resistance to available chemotherapy and biological therapy
regimens.375
OUTPATIENT HAPLOIDENTICAL STEM CELL TRANSPLANTATION IN PE-
DIATRIC PATIENTS. PRELIMINARY RESULTS IN A SINGLE INSTITUTION
IN MEXICO
Gonzalez, O., Rodrıguez, L.N., Mancıas, C., Tarın, L., Salazar, R.,
Jaime, J.C., Cantu, O.G., Gutierrez, H., Gomez, D. University Hospital,
UANL, Monterrey, Nuevo Leon, Mexico
Introduction: Hematopoietic cell transplantation (HCT) is a well-
established treatment for several nonmalignant and malignant
diseases in children. However, only 25% of children have an HLA
identical sibling, and a suitably matched unrelated donor does not
